Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

NCT ID: NCT02967718

Last Updated: 2016-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

13000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coronary heart disease is still the major cause of death in China. Chinese medicine plays more and more important role in CHD prevention and treatment. Phlegm and blood stasis are its major pathological basis. Based on that, the investigator aims to evaluate the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method so as to guide the clinical treatment of CHD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary heart disease (CHD) is a major cause of myocardial infarct (MI) and death induced by atherosclerosis or coronary artery spasm. Despite improvements in interventional and pharmacological therapy for acute MI, the mortality early after AMI remains high. Nowadays, as our life quality develops and dietary structure changes, the morbidity of hyperlipidemia dramatically increased. Based on the Chinese medicine, hyperlipidemia belongs to phlegm and it's the basis of atherosclerosis, blood-stasis is the pathological basis of ischemia. Therefore, the investigator proposes that phlegm and blood-stasis syndrome is the main differentiation on CHD. Based on that, the investigator prospectively and retrospectively explores the evolutionary process of CHD phlegm-blood stasis syndrome by large samples, multi-centre, cross-section observation combining with longitudinal tracking on-site survey method.It will provide evidence and guidance to the future clinical treatment using Chinese medicine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

the healthy patients

No interventions assigned to this group

Metabolic syndrome group

Include patients who are accordance with diagnostic criteria of metabolic syndrome

No interventions assigned to this group

CHD stable stage group

Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome

No interventions assigned to this group

Acute coronary syndrome group

Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction

No interventions assigned to this group

PCI or CABG group

Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting

No interventions assigned to this group

CHD heart failure group

Include the patients who suffered heart failure cause by CHD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy or metabolism syndrome people
* Clinical diagnosis of CHD stable stage or acute coronary disease or CHD heart failure

Exclusion Criteria

* Any inflammation, fever, trauma, burn or operation within 1 week
* Obstructive pulmonary disease
* Cerebral vascular disease
* Severe renal or hepatic dysfunction
* Malignant neoplasms
* Hematopoietic system disease
* Sever mental disease
Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jingqing Hu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jingqing Hu

Director of Institute of Basic Theory of Traditional Chinese Medicine

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Integrative Hospital of Beijing

Beijin, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weiming Xu, Doctor

Role: CONTACT

Phone: 86-15652608470

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yanhui Wang

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Zhang J, Tong H, Jiang L, Hu J. Dietary Patterns Associated With Heat Retention in Blood Vessel Syndrome (HRBVS) in Coronary Heart Disease: A Cross-Sectional Study. Int J Gen Med. 2025 Mar 5;18:1283-1294. doi: 10.2147/IJGM.S510507. eCollection 2025.

Reference Type DERIVED
PMID: 40062358 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014CB542903

Identifier Type: -

Identifier Source: org_study_id